Recently there has been a substantial growth in the vaccine market with the rising incidences of cancer & HIV cases. World Health Organization growth estimations indicate the market may increase in value to almost 17.83 billion in 2023, with the arrival of new therapeutic preventive, and adult vaccines.
Europe Preventive Vaccine Market is estimated at $9.99 Billion in 2018 and is poised to reach $ 17.83 billion by 2023 with a compound annual growth rate of 12.28 %.
The vaccine Market is quite different from any other product market, having distinct features with increased complexity of assessing, understanding prices and procurement. Although it is a small market compared to the pharmaceutical market, we cannot dismiss the fact that it is growing at a fast rate. There are currently around 120 new vaccines in the pipeline of various multinational companies across the world and are set to hit the market in the coming years. While the vaccine market is rather concentrated on both supply and demand sides, it is mostly dependent on public purchasers and donor policies.
Introduction of new vaccines for every other diseases is aiding the growth of vaccine market. Also, rise in the frequency of occurrence of infectious diseases like tuberculosis, hepatitis, diphtheria and pneumococcal diseases across the globe has increased the usage of vaccines. Invested from governments for vaccine development, increase in funding by the major market players, rising occurrence of disease, technological advancements decreasing the new vaccine development time drastically, initiatives by NGO’s are some of the factors that are propelling the growth of vaccines However, there are few factors restraining the growth of vaccine market like, huge capital expenditures and stringent regulatory policies by the governments, massive cost associated with treatment.
Europe Preventive Vaccine Market is segmented by type of vaccine as Live, attenuated vaccines, inactivated vaccines, Toxoid vaccines, Subunit vaccines, Conjugate vaccines, DNA vaccines and Recombinant vector vaccines. In addition, based on age groups the market is categorized as Paediatric Vaccine (Pneumococcal, MMR, Varicella, Hepatitis, Poliovirus, HIB and others) and Adult vaccines (Influenza, Cervical Cancer, Hepatitis, Zoster and others). Furthermore, on the basis of geography, the European Market is analysed under various regions namely, UK, Spain, Italy, Germany and France.
Historically many of the multinational vaccine companies have been investing huge sums in research and development resulting in new innovations in the market. The major players in the preventive vaccine market are GlaxoSmithKline, plc, Merck and Company, Bavarian Nordic, CSL Limited, Emergent BioSolutions Inc., Novartis AG, Johnson and Johnson, MedImmune, LLC, Pfizer, Inc., and Sanofi Pasteur.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 By Vaccine Type
5.1.1 Live, Attenuated Vaccines
5.1.2 Inactivted Vaccines
5.1.3 Toxoid Vaccines
5.1.4 Subunit vaccines
5.1.5 Conjugate vaccines
5.1.6 DNA vaccines
5.1.7 Recombinant vector vaccines
5.2 By End User
5.2.1 Paediatric Vaccine
5.2.1.1 Pneumococcal
5.2.1.2 MMR
5.2.1.3 Varicella
5.2.1.4 Hepatitis
5.2.1.5 Poliovirus
5.2.1.6 HIB
5.2.1.7 Others
5.2.2 Adult Vaccines
5.2.2.1 Influenza
5.2.2.2 Cervical Cancer
5.2.2.3 Hepatitis
5.2.2.4 Zoster
5.2.2.5 Others
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 GlaxoSmithKline, plc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Merck and Company
8.3 Bavarian Nordic
8.4 CSL Limited
8.5 Emergent BioSolutions Inc.
8.6 Novartis AG
8.7 Johnson and Johnson
8.8 MedImmune, LLC
8.9 Pfizer, Inc.
8.10 Sanofi Pasteur
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
